Pfizer Inc. PFE on Tuesday announced topline results from the Phase 2 FOURLIGHT-1 study in pretreated metastatic breast ...

Pfizer (PFE) announced on Tuesday that its investigational breast cancer therapy, atirmociclib, as part of a combination regimen, reached the main goal in a mid-stage trial for certain patients with ...

Pfizer’s CDK4 inhibitor, atirmociclib, is already being investigated in a Phase III trial as a first-line therapy.

A phase 2 study of Pfizer’s atirmociclib has hit its primary endpoint, providing evidence that the CDK4 inhibitor improves progression-free survival (PFS) in second-line metastatic breast cancer. But ...

Pfizer's Phase 3 trial showed sasanlimab with BCG improved event-free survival in high-risk NMIBC patients. Sasanlimab's safety profile aligns with known PD-1 inhibitors and BCG data from previous ...

The drug, which one analyst described as a “critical” part of Pfizer’s oncology strategy, represents a possible improvement upon Ibrance and other, similar breast cancer medicines from Eli Lilly and ...

Pfizer (NYSE:PFE) and Astellas Pharma reported positive pivotal Phase 3 results for PADCEV plus Keytruda in muscle invasive bladder cancer. The EV-304 (KEYNOTE-B15) trial showed a substantial ...

While sales of Talzenna, which Pfizer acquired in a $14 billion deal, have been “negligible” so far, the new results should ...

Pfizer (NYSE:PFE) has started a Phase 1 trial of a new tafamidis tablet formulation aimed at improving manufacturing ...

Pfizer is betting on a new breast cancer drug combo that, in a key mid-stage trial, cut the risk of the disease worsening or patients dying by about 40% for a particularly tough-to-treat group.

In early March 2026, Pfizer reported past Phase 2 trial results showing its investigational trispecific antibody tilrekimig significantly improved eczema severity versus placebo in adults with ...